Figure 1From: Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE studyPatient flow through the double-blind and open-label phases. AE, adverse event; DB, double-blind; ETN, etanercept; OL, open-label; PBO, placebo.Back to article page